Menu
Recruiting NCT06899841

Dexmedetomidine in Sonographic Guided Erector Spinae Plane Block

Phase II / Phase III Interventional Pain Management

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Dexmedetomidine.
Who it may be relevant to
Registry conditions: Pain Management. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effect of Different Doses of Dexmedetomidine Added to Local Anesthetic in Sonographic Guided Erector Spinae Plane Block for Pain Management After Renal Surgeries : Randomized Clinical Trial

Overview

to investigate the postoperative analgesic effect of dexmedetomidine addition with different doses as an adjuvant to bupivacaine to Erector spinae plane block after renal surgeries.

Interventions

  • Drug Dexmedetomidine
    different doses of dexmedetomidine added to bupivacaine in erector spinae plane block

Primary outcome measures

  • postoperative analgesic duration [Time frame: 24 hours]
Secondary outcome measures (3)
  • Pain score [Time frame: 24 hours]
  • side effects [Time frame: 24 hours]
  • dynamic pain score [Time frame: 24 hours]

Eligibility criteria

Inclusion criteria

  • Age between 18 and 70 years.
  • Both sexes, males and females.
  • Patients with the American Society of Anesthesiologists (ASA) physical status I/II.
  • Body mass index (BMI) of 18-35 kg/m2
  • Patients scheduled for elective Renal or Percutaneous Nephrolithotomy.

Exclusion criteria

  • Patients under 18 years.
  • Patient refusal of nerve block.
  • Infection at the site of injection.
  • Coagulopathy.
  • Allergy to used medications.
  • Psychiatric disorder or chronic pain syndromes.
  • Chronic opioid use or substance abuse.
  • Quadriplegic patients.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Assiut University Hospitals — Asyut

Identifiers

NCT: NCT06899841 · 04-2024-200943

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗